Schrodinger president Karen Akinsanya sells $927,970 in company stock

On September 17, 2026, Karen Akinsanya, the President, Head of Therapeutics R&D, and Chief Strategy Officer at Schrodinger, Inc. (SDGR), sold 31,599 shares of the company's common stock. The sales amounted to a total value of $927,970, with each share priced between $28.00 and $30.00. This transaction occurred as SDGR's stock price neared its 52-week high of $31.03, following a 152% increase over the past six months.

The sale was made in accordance with a Rule 10b5-1 trading plan Akinsanya put in place on November 11, 2025. Prior to the sale, Akinsanya purchased 31,599 shares by exercising stock options on November 29, 2018, at $4.34 per share, resulting in a total investment of $137,139. This option became fully vested on the same day as the stock sale.

After these transactions, Akinsanya now owns 69,956 shares of SDGR common stock, which includes 63,545 restricted shares that have not yet vested.